Analyzing Global Cord Blood (NYSE:CORBF) and Marpai (NASDAQ:MRAI)

Marpai (NASDAQ:MRAI) and Global Cord Blood (NYSE:CORBF) are both small-cap business services companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Profitability

This table compares Marpai and Global Cord Blood’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Marpai	-77.38%	N/A	-75.05%
Global Cord Blood	N/A	N/A	N/A

Risk & Volatility

Marpai has a beta of 5.41, suggesting that its stock price is 441% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500.

Institutional & Insider Ownership

49.8% of Marpai shares are owned by institutional investors. 61.3% of Marpai shares are owned by company insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Marpai and Global Cord Blood, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0	0	1	0	3.00
Global Cord Blood	0	0	0	0	N/A

Marpai currently has a consensus price target of $6.00, suggesting a potential upside of 141.94%. Given Marpai’s higher possible upside, analysts plainly believe Marpai is more favorable than Global Cord Blood.

Valuation and Earnings

This table compares Marpai and Global Cord Blood’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$37.16 million	0.69	-$28.75 million	($4.41)	-0.56
Global Cord Blood	$196.12 million	0.77	$79.04 million	N/A	N/A

Global Cord Blood has higher revenue and earnings than Marpai.

About Marpai

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, bill review and cost containment services. It also develops artificial intelligence and healthcare technology. Marpai, Inc. was incorporated in 2021 and is headquartered in New York, New York.

About Global Cord Blood

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.